HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory Roulette: Playing In Today’s Skin-Care Market A Gamble

This article was originally published in The Rose Sheet

Executive Summary

Recent FDA warning letters to skin-care firms raise questions about the regulatory risks companies must assume to compete effectively in today’s marketplace. Former FDAer and EAS Senior Adviser John Bailey discusses the strategic decision before personal-care companies as they develop their marketing and the potential consequences of using structure/function claims.

You may also be interested in...



ASA: Olay Regenerist 'Cell By Cell' Exfoliation Claims Imply 'Physiological' Effects

Ads claiming P&G's Olay Regenerist skin-care line “re-energizes skin’s appearance cell by cell” mislead consumers into expecting deeper cellular changes rather than mere surface exfoliation, an implied benefit unsupported by the firm's evidence, according to the UK’s independent regulator.

FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims

FDA cites Reviva for unapproved drug claims on eight of its products marketed as cosmetics. Included among targeted claims are familiar statements about collagen production, inflammation reduction and other benefits the agency views as structure/function effects. A number of the claims onceivably could be allowed under the revised "cosmetic" definition proposed by the Cosmetic Modernization Amendments of 2015.

Athena Appeal Decision Could Open ‘Floodgate’ For False Claims Litigation

Lower court decisions that Athena Cosmetics’ RevitaLash products is an unapproved drug competing unfairly against Allergan's Latisse drug could have broader implications if the Supreme Court denies the firm's request for review. Already beleaguered by class actions following FDA warnings, firms could face more opportunistic lawsuits if federal courts are left to determine a product's intended use and regulatory status.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS019420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel